A new progestin (Sa 45.249) for cycle control in pigs communication I: Hormonal activities and dosage

Sa 45.249 was applied for 12 days to groups of ten gilts each. A daily dose of 3, 6, 12 or 24 mg inhibited cyclic functions effectively; estrus was observed 4.5 ± 0.8, 4.8 ± 0.8, 5.2 ± 0.9 and 6.1 ± 0.6 days after cessation of treatment, respectively. All animals were slaughtered 8 days after induced estrus. Only animals treated with 3 mg showed a high incidence of ovarian cysts simultaneously with the occurrence of corpora lutea. In animals treated with higher dosages, only one (6 mg) had 4 cystic follicles, but simultaneously 12 corpora lutea. In another study, the effectiveness of Sa 45.249, applied at different doses, for differing time periods, and starting at different days of the cycle, was investigated. Doses ranged from 3 to 9 mg/day, duration of treatment from 8 to 16 days and treatments commenced on days 2, 5, 10, 15 or 19 of the cycle. An increase in the daily doses of 1 mg resulted in a delay of estrus of less than 0.1 day. Of 99 gilts, 93 showed an estrus 6.5 ± 1.7 days after cessation of treatment. None of the variables studied had a significant effect on the occurrence of estrus or the interval between treatment and the onset of heat.     

A study of prostaglandin F2α as the luteolysin in swine: I. Effect of prostaglandin F2α in hysterectomized gilts

Experiments were conducted to determine if prostaglandin F_2α (PGF_2α) is luteolytic in swine. In Experiment 1, four bilaterally hysterectomized gilts were injected with PGF_2α at 0800 (10mg) and 2000 hours (10mg) and four gilts received .9% saline at the same times on day 17 after onset of estrus. Treatments were reversed in the two groups of gilts 21 days later. All eight PGF_2α treated gilts exhibited estrus an average of 88.0 ± 13.5 hours after treatment and average duration of estrus was 66.0 ± 16.4 hours. Saline treated controls did not exhibit estrus. Two additional gilts were hysterectomized bilaterally and the saphenous artery catheterized on day 7 after onset of estrus. PGF_2α injected on day 17 resulted in a precipitous decline in plasma progestin concentration and onset of estrus by 110 and 90 hours in gilts 1 and 2, respectively. Another bilaterally hysterectomized gilt, with CL marked with India ink, received PGF_2α on day 17. Estrus occurred 92 hours later and, on day 4, regression of marked CL to corpora albicantia and presence of newly formed CL was confirmed at laparotomy.In Experiment 2, 12 bilaterally hysterectomized gilts were treated with PGF_2α at 0800 (10mg) and 2000 hours (10mg) on either day 8, 11, 14 or 17 after onset of estrus. None of the gilts treated on days 8 and 11 exhibited estrus. Two of three gilts treated on day 14 and all three gilts treated on day 17 exhibited estrus at an average of 116.0 ± 9.8 hours post-treatment. Average duration of estrus was 49.6 ± 8.8 hours.     

Clinical evaluation of a new prostaglandin analog in pigs: 2. Prophylaxis and therapy of anestrus after weaning in sows and first litter gilts

Alfaprostol, a new prostaglandin F(2alpha) (PGF) analog was given in a first trial at two dose levels known to be luteolytic (1 and 2 mg) to 200 sows and first litter gilts at the day of weaning after a 21-day lactation period; 189 controls received saline only. The treatment with alfaprostol shortened the interval to heat (6.0 vs 11.3 days; p<0.01) and increased the percentage of animals coming into heat within 10 days (84.0 vs 65.5%; p<0.01). Fertility to a.i. and litter size at the subsequent parturition were normal. In a second trial, 100 first litter gilts and 100 sows received alfaprostol, 1 or 2 mg, respectively, during July and August when high environmental temperatures tend to increase the rate of anestrus. Again, treatment with alfaprostol shortened effectively the interval to heat (5.9 vs 17.4 days in gilts, p<0.001; 5.6 vs 9.7 days in sows; p<0.01) and greatly increased the number of animals in heat (81 vs 47% in gilts, 83 vs 62% in sows; p<0.001). The effect on the seasonal incidence of clinical anestrus was marked; it was more pronounced in gilts than in sows, expressed by the length of time it took to resume cyclic functions and the lower percentage of animals coming into heat (p<0.001). The effect of alfaprostol was equally well expressed in first litter gilts and sows. In a third trial, 295 anestrous sows and gilts were treated on day 22 after weaning with either 2 mg alfaprostol, or 400 I.U. PMSG+200 I.U. hCG, or saline. Within five days after weaning, 38% of the alfaprostol treated, and 78% and 23% of the animals treated with PMSG/hCG and saline came into heat.     

Effects of Zeranol upon luteal maintenance and fetal development in peripubertal gilts

Eighty gilts were utilized to determine whether zeranol implants could maintain hCG-induced corpora lutea (CL) in peripubertal gilts and to examine the effects of a Zeranol implant on fetal development. Crossbred gilts (171+/-0.3 days of age, 109.1+1.4 kg) were blocked by weight and ancestry to control (n=40) or treatment (n=40) groups. To induce ovulation and CL maintenance, treated gilts received 500 IU of hCG i.m. and a Zeranol ear implant (Ralgro, 36 mg; day 0). All gilts were checked once daily for estrus with a mature boar from days 3-58 of the experiment. On day 42, treated gilts received two 10 mg injections of Lutalyse (PGF(2)alpha) spaced 6 h apart. Treated gilts not displaying estrus within 7 days of PGF(2)alpha received two additional 10 mg of PGF(2)alpha spaced 6 h apart on day 49. On days 44-58, gilts detected in estrus were inseminated twice, 24 h apart with pooled semen via AI. Blood samples were obtained on days 0, 7, 18 and 42 and analyzed for serum progesterone (P(4)). Bred gilts were slaughtered on days 58-62 of gestation. Ovulation, as determined by serum concentrations of P(4) on day 7 of the experiment, was induced by hCG in 79.5% of treated gilts. Zeranol implants, however, failed to increase (P>0.05) the proportion of gilts available for breeding (treated, 21/39; control, 18/40). Of gilts inseminated on days 44-58, 16/21 treated gilts and 16/18 control gilts were pregnant at slaughter on days 58-62 of gestation. Number of fetuses (7.5 versus 12), fetal weight (83 versus 121 g), fetal length (117 versus 132 mm) and fetal survival (45% versus 78%) were reduced (P<0.001) by Zeranol implants. These data indicate that treatment of peripubertal gilts with a 36 mg Zeranol implant did not increase the proportion of gilts available for breeding while causing deleterious effects upon the fetuses.     

Uptake and effects of ovarian steroids in the early pig embryo: In vitro and in vivo studies

The role of ovarian steroids in the preimplantation pig embryo was studied in vivo and in vitro. Twenty gilts were treated three times daily on days 1 to 4 after insemination with either 25, 100, 250, or 1000 mg progesterone in oil, and 17 gilts were injected with corresponding amounts of sesame oil (controls). All gilts were slaughtered 5 days after insemination and the embryos were recovered. Oviduct and plasma progesterone content were significantly (P<0.001) higher in gilts treated with 750 mg of exogenous progesterone per day. After 750 mg progesterone, oviduct progesterone content was twice as high as control levels, while after 3000 mg progesterone per day the levels in oviduct and uterus exceeded those of controls by five and seven times, respectively. In gilts treated with 750 mg progesterone per day, plasma progesterone levels were 177.4 ± 22.1 ng/ml ($\text{x}\text{±}\text{SD}$) on day 3 and 186.4 ± 69.2 ng/ml on day 5 and resembled values found in superovulated pigs with more than 40 ovulations. Excessive plasma progesterone values of 1014.6 ± 840.4 ng/ml on day 3 and 473.2 ± 197.2 ng/ml on day 5 were found after treatment with 3000 mg of progesterone per day. Treatment with up to 750 mg of exogenous progesterone per day, did not affect embryonic development, but 3000 mg per day resulted in a significantly (P<0.001) higher percentage of retarded and degenerate embryos compared to controls (71.8% versus 3.2%).In addition, the amount and specificity of uptake of ³H-labelled progesterone and estradiol-17 beta by pig blastocysts recovered from superovulated gilts were investigated after 6 hrs in vitro culture. The uptake of ³H-progesterone was 131.9 ± 56.9 counts per million (cpm) per 10 blastocysts, corresponding to 1.1 fmoles progesterone. The uptake was non-specific for it was only slightly reduced in the presence of a 100-fold excess of unlabelled progesterone (20.1%) or estradiol-17 beta (27.0%). The uptake of ³H-estradiol-17 beta was 133.9 ± 74.12 cpm per 10 blastocysts, corresponding to 1.3 fmoles estradiol-17 beta. The uptake was significantly (P<0.01) reduced by 67.7% in the presence of a 100-fold excess of unlabelled estradiol-17 beta. Apparent specific binding was 0.87 fmoles estradiol-17 beta per 10 blastocysts or 72.5 fmoles estradiol-17 beta per mg protein. The uptake was only slightly reduced in the presence of a 100-fold excess of unlabelled progesterone (23.3%). This significant inhibition could be determined after 2 hrs in vitro culture. There was no competitive inhibition after 20 min. of culture.Uptake by unfertilized ova and degenerate embryos recovered on day 5 was significantly smaller (51.8 ± 10.3 cpm per 10 eggs; P<0.001) than by blastocysts recovered on the same day. No competitive inhibition could then be determined. In vivo, preimplantation pig embryos seem to be rather insensitive to high progesterone levels. Excessive amounts of progesterone probably can be metabolized to a great extent. Progesterone seems to be taken up rather non-specifically by the pig embryo. The uptake and binding of estradiol-17 beta seems to be more specific. Studies are in progress to investigate the physiological role of estradiol-17 beta uptake in early embryonic development.     

Effects of injection of hcg during the estrous cycle on follicle development and the inter-estrous interval

Pseudopregnancy in pigs can be induced by the administration of a single dose of hCG at Day 12 of the estrous cycle. However, the resulting length of pseudopregnancy can be extremely variable. In this study, it was investigated whether time of hCG administration (day of the cycle) and degree of follicle growth after hCG administration were related to the length of inter-estrous interval (pseudopregnancy). In the first experiment, groups of cyclic gilts were given 1500 IU hCG at either Day 11 (D 11; n=14) or Day 12 (D12; n=14) after onset of estrus, or not treated (Control; n=13). Follicle development was assessed daily using transcutaneous ultrasonography. Follicle size in the Control gilts remained relatively constant between Days 11 and 17, whereas in the treated gilts, follicle size increased (P < 0.001) within 4 days (D11) and 2 days (D12) after treatment. The inter-estrous interval was increased (P < 0.01) in the hCG-treated gilts (34.7+/-6.3 and 37.6+/-11.1 days in the D11 and D12 gilts, respectively), compared to Controls (22.3+/-5.2 d). About two-thirds of the treated gilts returned to estrus between Days 32 and 39 after onset of first estrus. No relationships were found between follicle development after treatment and length of the inter-estrous interval. In a second experiment, 16 cyclic gilts were treated with 1500 IU hCG at Day 12 and Day 15 of the estrous cycle. Follicle development was assessed at Days 12, 15 and 18. At Day 18, average follicle size was 8.4+/-2.0 mm. The inter-estrous interval was 39.7+/-5.4 days and 14 of 16 gilts returned to estrus between Days 34 and 44 after onset of first estrus. Again, no relationships were found between follicle development after treatment and the duration of the inter-estrous interval. We conclude that, based on the duration of the inter-estrous interval, administration of hCG during the luteal phase induced a short pseudopregnancy. However, the induction of accessory corpora lutea or follicular luteinization cannot be discounted.     

Control of estrus in the lactating postpartum mare with fluprostenol (ICI-81,008)

During the 1976 breeding season 68 mares (56 Thoroughbred and 12 Quarter Horse) were allotted to 4 treatment groups. On day 7, 8 or 9 post-ovulation or day 6, 7 or 8 after foal heat each of 28 mares was injected intramuscularly with 250 μg of the prostaglandin analogue ICI-81,008 (generic name fluprostenol). In the second group, 32 mares were bred at foal heat. Group 3 consisted of 9 mares, which were passed at foal heat and bred at the second postpartum estrus. In group four, 12 of the mares which had failed to conceive at foal heat were bred at the second estrus. Twenty-four prostaglandin treated mares returned to estrus 4.2±.4 days post-injection. The interestrual interval was shorter (P<.05) for prostaglandin treated mares (11.4±.6 days) than for previously mated second heat control mares (19.2±2.3). Also, the interval between parturition and second estrus was decreased (P<.05) in treated mares (24.5±.8 days) compared to group three (32.8±2.5 days). Duration of the second postpartum estrus was similar for both treated and control mares. Plasma progesterone levels in prostaglandin treated mares as determined by RIA were 7.5±.5 and 6.9±.5 ng/ml before treatment and at l hour post-injection, then dropped precipitously to near undetectable levels at 48 hours after injection. Pregnancy rate at 45 days was significantly higher (P<.05) in prostaglandin treated mares (78%) as compared to foal heat mares (48%) and mares which were passed at foal heat and bred at the second postpartum estrus (44%).     

Regulation of the estrous cycle in ewes with progestin containing implants: Influence of dose and day of cycle at treatment

Implants containing Norgestomet (G. D. Searle and Co., Chicago) were inserted subcutaneously in ewes on selected days of the estrous cycle. When ewes were treated for 13 days with 2 or 3 mg Norgestomet, implantation 13 days post-estrus reduced the number of ewes in estrus within 5 days of implant removal and reduced the number of estrous ewes that lambed compared with ewes implanted 4 days post-estrus. When ewes were implanted with 3 or 6 mg Norgestomet 4 or 13 days post-estrus, no difference in estrus response was found. Conception rate was not influenced by day of treatment, but was higher in those ewes treated with 6 mg than ewes treated with 3 mg. Compared to no treatment, treatment with 3 or 6 mg Norgestomet reduced the number of uterine and oviducal sperm recovered 12 or 24 hr after insemination from ewes implanted for 12 days 2 or 12 days post-estrus. However, more sperm were recovered from ewes treated 2 days than 12 days post-estrus with the principal increase occurring in ewes treated with 6 mg of Norgestomet.     

Synchronization of oestrus in gilts with altrenogest: effects on ovulation rate and foetal survival

Previous studies have shown that use of altrenogest resulted in a high rate of fertility and increased litter size compared with controls under conditions of practical pig production. The present study was designed to evaluate whether ovulation rate and/or foetal survival were increased by altrenogest using crossbred gilts derived from one herd (n = 227) and introduced in the same piggery over 12 months. Each gilt was allocated to a treated group (n = 103) receiving an individual daily dose of 20 mg of altrenogest for 18 days in its feed or a control group (n = 124) after puberty had been diagnosed, (197 ± 1 day; mean ± SEM). They were inseminated (double AI) at the second induced or natural oestrus. Pregnancy was diagnosed by ultrasonography at Days 22 and 42 post-insemination in the absence of return to oestrus. Pregnant gilts were slaughtered at 48 ± 3 days of pregnancy following the second examination. The number of living and dead foetuses were recorded before uterine contents (foetuses and placentae) were weighed and the number of corpora lutea (CL) per ovary counted.Precise synchronization of oestrus was observed after the end of the progestogen administration, with 93% of the gilts in oestrus by Days 5 to 7. For the controls, the interval from first to second oestrus ranged from 17 to 25 days in 93% of the control gilts. The pregnancy rate was 89.3% for treated gilts and 77.4% for controls (P < 0.05). The ovulation rate was increased by the treatment (15.4 ± 0.3 vs 14.6 ± 0.3; mean ± SEM, P < 0.02). Although the altrenogest group had more foetuses (11.1 vs 10.6), this difference was not significant (P > 0.14). The percent of foetal survival was similar in both groups (64.9%; P > 0.27). The foetal and placental weights differed only between dams and increased with stage of gestation. The increase in litter size through feeding altrenogest was associated with an increased ovulation rate.     

Effect of prior FSH treatment on the estrus and ovulation responses to eCG in prepubertal gilts

The objective of this study was to determine the effect of pre-treatment of prepubertal gilts with FSH on the estrus and ovulatory responses to eCG injection at two ages. A total of 149 prepubertal Hypor gilts were selected at 150 days (n=76) or 180 days (n=73) of age and assigned to injection of 400 IU eCG plus 200 IU hCG (PG600), 600IU eCG alone (Folligon), pre-treatment with 72 mg FSH (Folltropin) administered as 6 x 12 mg injections at 12 h intervals with 600 IU Folligon 12h after last FSH injection, or non-injected controls. To facilitate detection of estrus, gilts were exposed to a mature boar for 15 min daily for 7 days. To determine ovulatory responses, blood samples were obtained on the day of injection and 10 days later and assayed for progesterone content. Following treatment at 150 days, one control gilt (5.3%) was deemed estrus but ovulation did not occur. Compared to treatment with Folligon alone, PG600 injection tended (P=0.1) to increase the estrus response (52.6% compared with. 26.3%) and increased (P<0.01) the ovulatory response (89.5% compared with. 47.4%). The estrous response in gilts pretreated with Folltropin was intermediate (42.1%) but the ovulatory response (47.4%) was the same as for Folligon alone. Following treatment at 180 days, two control gilts (10.5%) were deemed estrus and ovulation did occur in these gilts. There was no difference between hormone-treated groups for estrus or ovulatory responses, although the ovulatory response of PG600-treated gilts tended (P=0.1) to be greater than for the Folligon-treated group (89.5% compared with 66.7%), with Folltropin-pretreated gilts being intermediate (76.5%). These data demonstrate that the estrus and ovulatory responses of gilts were greater for PG600 than for Folligon and that while responses to PG600 were not affected by gilt age, for the combined Folligon groups, estrous response (P<0.02) and ovulatory response (P<0.05) improved with increased gilt age.     

Pre- and Postpubertal LH and Estradiol Pattern in Gilts Subjected to Intermittent Inescapable Electroshock

The effect of intermittent electroshock on LH and es-tradiol secretory pattern and on reaching puberty was studied in 24 prepubertal gilts. Twelve gilts 115-168 days of age received unpredictable and inescapable electroshocks 0-5 times daily between 8 am and 4 pm and 12 gilts served as controls. At an age of 168 ± 0.7 days all gilts were moved, regrouped and exposed to a boar for 30 min. Observa-tions for signs of oestrus were carried out twice daily. Indwelling jugular catheters were inserted into 8 gilts on each treatment after the initial boar contact. Blood samples were collected to determine LH profiles for 4 h every 15 min on day 2 and day 4 after the in-itial boar contact. The remaining 4 gilts on each treatment were catheterized one day prior to the initial boar contact and blood was collected to determine LH profiles the day before initial boar contact and day 1 and day 2 after initial boar contact for 6 h every 15 min. In addition, blood samples were collected and analyzed for LH and estradiol from all gilts daily at 8 am, 12 am and 4 pm for the first 3 days following the initial boar con-tact and thereafter every 4 h until the end of oestrus (diurnal samples). Samples taken daily at noon the first 5 days following initial boar contact were analyzed for Cortisol. The electroshock treatment significantly increased the age at puberty (p=0.04) and tended to decrease the mean LH concentration prior to the preovulatory LH surge (p=0.08) and the maximal concentration of LH during the preovulatory LH surge (p=0.07). The apparent down regulation of the plasma concentration of LH was not as-sociated with increased activity in the hypothalamus-pituitary-adrenal axis in that the basal concentration of Cortisol was not affected by treatment. This indicates that other physiological mechanisms are involved in stress-induced suppression of LH.     

A study of prostaglandin F2α as the luteolysin in swine: III effects of estradiol valerate on prostaglandin F, progestins, estrone and estradiol concentrations in the utero-ovarian vein of nonpregnant gilts

Polyvinyl catheters were placed into the right and left utero-ovarian veins and saphenous vein and artery of three control (C) and four estradiol valerate (EV) treated gilts on Day 9 after onset of estrus. The EV treated gilts received 5mg EV/day on Days 11 through 15 after onset of estrus. On Days 12 through 17 utero-ovarian vein blood samples were collected at 15 min intervals from 0700 to 1000 hr and 1900 to 2200 hr and single samples were taken at 1100 and 2300 hr. Peripheral blood samples (saphenous vein or artery) were taken at 0700, 1100, 1900 and 2300 hr from Day 12 until the control gilts returned to estrus or until Day 25 for EV treated gilts and used to measure plasma steroid hormone concentrations. Utero-ovarian vein prostaglandin F (PGF) concentrations (ng/ml, n=1,177) were measured by RIA. Status (control EV treated gilts) by day interactions were detected (P=.10). Curvilinear day trends were detected for plasma PGF concentrations in control (P<.01) but not EV treated gilts. PGF concentrations ( ) for control and EV treated gilts were 1.20 ± 2.08 and .26 ± .84 ng/ml, respectively. PGF peaks (concentrations greater than + 2 S.D.) occured with greater frequency in control gilts (X² = 4.87; P<.05). The interestrus interval ( ) for control and treated gilts was 19.0 ± .6 and 146.5 ± 74.8 days, respectively. Data indicate that estradiol valerate may exert its luteotrophic effect by preventing PGF release from the uterus.     

Influence of induced delayed parturition on fetal survival in pigs

Pregnancy was prolonged as long as 23 days in gilts receiving daily oral 6-methyl-17 acetoxy-progesterone (MAP) at a level of 0.27–0.41 mg/kg body weight. These levels of progestin did not effect fetal welfare if administered throughout gestation and did not interfere with normal parturition and live litter size if treatment was terminated at the calculated term date which corresponded with the day of milk let-down. The initiation of milk let-down was not effected by treatment. Severe fetal death occurred in all gilts delivering young naturally during prolonged pregnancy and in gilts whose litters were delivered surgically 12 days or more after milk let-down. Mean live litter size was normal in gilts whose young were delivered surgically within 11 days of milk let-down. Fetal death at 12 days or more of prolonged pregnancy was attributed to placental insufficiency. The reproductive parameters studied were unaffected by the addition of 0.001 to 0.013 mg/kg body weight of diethylstilbestrol (DES) to the progestin treatment or the use of this agent alone.     

Estrus and ovulation in gilts fed a synthetic progestogen

A synthetic progestogen, allyl trenbolone (AT), was fed to sexually mature gilts to determine the effective doses for the control of estrus and ovulation. Gilts were assigned to a control group and 5 treatment groups receiving 10.0, 12.5, 15.0, 17.5 or 20.0 mg of AT mixed in .45 kg of feed/head/day for 18 consecutive days. Ovarian morphology was determined by laparotomy following estrus or at 10 days post-treatment. AT suppressed estrus in all gilts during treatment. Estrus was effectively synchronized in treated gilts. The average interval from withdrawal of progestogen treatment to estrus was 4.5 days for 48 of 50 treated gilts that were in estrus within 10 days after treatment. The average ovulation rate in treated gilts was similar to control gilts. No detrimental side effects, due to treatment, were observed with the possible exception of a slight increase in the incidence of cystic follicles.     

Adrenocorticotropin administration during early gestation on conceptus development in swine

The purpose of this study was to examine the effect of exogenous adrenocorticotropin (ACTH), administered to gilts during early stages of gestation, upon fetal survival and various maternal and conceptus parameters. Forty-eight gilts of approximately 6-7 months of age were bred by means of artificial insemination after detection of the second estrus and randomly allotted to one of 12 treatment-period groups. Treatment consisted of a daily intramuscular injection of 0, 40 or 80 U.S.P. units of a long acting ACTH preparation for a period of five days. The injection periods were 1-5, 6-10, 11-15 or 16-20 days of gestation with day one corresponding to 48 hours post-estrus detection. All gilts were slaughtered at approximately 37 days of gestation. Forty-two of the 48 inseminated gilts conceived. Conception rate was not different (P>.10) among the 12 treatment-period combinations. Percent fetal survival was greater (P<.09) in gilts receiving 80 U.S.P. units of ACTH (82 +/- 4.3%; X +/- SEM ) than in gilts receiving 40 U.S.P. units of ACTH (68.8 +/- 4.5%). The percent fetal survival in the control group (71.7 +/- 3.9%) was not different (P>.10) from either of the two ACTH treatment groups. A significant (P<.05) treatment by period interaction for percent fetal survival was observed. The lowest percent fetal survival (48.0 +/- 9.0%) was observed in gilts receiving 40 U.S.P. units of ACTH on day 11-15 of gestation. No significant (P>.10) differences were detected among the 12 treatment-period combinations for any of the maternal or conceptus parameters measured.     

Seasonal inhibition of puberty in domestic gilts is overcome by melatonin administered orally, but not by implant.

The ability of exogenous melatonin, applied either orally or by implant, to overcome the seasonal inhibition of puberty in domestic gilts was tested in two experiments. In Expt 1, 24 gilts received two melatonin implants at 126 days of age and again at 161 days and 196 days, while 24 gilts acted as controls. All gilts were slaughtered at a mean age of 223 days. Blood samples were collected by venepuncture from eight gilts in each treatment at 126, 144 and 178 days of age and the plasma was assayed for melatonin concentration by direct radioimmunoassay. In Expt 2A, four gilts (125 days of age) were fed either 0, 1, 2 or 4 mg of melatonin at 14:00 h on each of four consecutive days. Blood samples for melatonin assay were collected via indwelling jugular catheters every 30 or 60 min from 12:00 to 22:00 h. In Expt 2B, 27 gilts were fed 1 mg of melatonin at 15:00 h each day from 129 days of age until slaughter at 221 days, while 25 gilts acted as controls. In both experiments, the presence of morphologically normal corpora lutea at slaughter was the criterion for puberty. In Expt 1, constant-release melatonin implants had no effect on the percentage of gilts which reached puberty. Among the 24 control gilts, two (8.3%) reached puberty compared with one of the 24 (4.2%) gilts with implants. In all the samples from control gilts, and in the samples taken from treated gilts prior to implantation at 126 days of age, mean plasma melatonin concentration was below the sensitivity of the assay (3.6 pg/ml).(ABSTRACT TRUNCATED AT 250 WORDS)     

Prostaglandin-induced regression of porcine corpora lutea maintained by estrogen.

Corpora lutea were marked with suture in 24 crossbred gilts on day 7 to 9 of the estrous cycle (first day of estrus equals 0). All gilts were injected with 5 mg of estradiol benzoate (EB) daily from day 10 to 15 to extend the lifespan of corpora tutea, then the gilts were randomly assigned to two groups. On day 20, the 12 gilts of Group 1 were injected with 10 mg PGF-2ALPHA, and the 12 gilts of Group 2 were injected with saline. Ovaries were recovered 10 to 13 days after PGF-2ALPHA or saline injection. Ten gilts in Group 1 displayed estrus 5 plus or minus 0.7 days after PGF-2ALPHA injection, but only two gilts in Group 2 displayed estrus during the experimental period. In gilts that displayed estrus, all marked CL had regressed. Marked CL were still present in all 12 gilts that failed to exhibit estrus during the experimental period. These results show that in the pig, PGF-2ALPHA caused regression of CL that were maintained beyond the normal luteal phase of the estrous cycel by EB treatment.     

A study of prostaglandin F2alpha as the luteolysin in swine: III effects of estradiol valerate on prostaglandin F, progestins, estrone and estradiol concentrations in the utero-ovarian vein of nonpregnant gilts

Polyvinyl catheters were placed into the right and left utero-ovarian veins and saphenous vein and artery of three control (C) and four estradiol valerate (EV) treated gilts on Day 9 after onset of estrus. The EV treated gilts received 5mg EV/day on Days 11 through 15 after onset of estrus. On Days 12 through 17 utero-ovarian vein blood samples were collected at 15 min intervals from 0700 to 1000 hr and 1900 to 2200 hr and single samples were taken at 1100 and 2300 hr. Peripheral blood samples (saphenous vein or artery) were taken at 0700, 1100, 1900 and 2300 hr from Day 12 until the control gilts returned to estrus or until Day 25 for EV treated gilts and used to measure plasma steroid hormone concentrations. Utero-ovarian vein prostaglandin F (gf) concentrations (ng/ml, n-1,177) were measured by RIA. Status (control vs EV treated gilts) by day interactions were detected (P=.10). Curvilinear day trends were detected for plasma PGF concentrations in control (P less than .01) but not EV treated gilts. PGF concentrations (X +/- S.D.) for control and EV treated gilts were 1.20 +/- 2.08 and .26 +/- .84 ng/ml, respectively. PGF peaks (concentrations greater than X + 2 S.D.) occurred with greater frequency in control gilts (X2 =4.87; P less than .05). The interestrus interval (X +/- S.E.) for control and treated gilts was 19.0 +/- .6 and 146.5 +/- 74.8 days, respectively. Data indicate tht t estradiol valerate may exert its luteotrophic effect by preventing PGF release from the uterus.     

Alteration of gonadotrophin and steroid hormone release, and of ovarian function by a GnRH antagonist in gilts

This study examined the impact of the gonadotrophin-releasing hormone (GnRH) antagonist Antarelix on LH, FSH, ovarian steroid hormone secretion, follicular development and pituitary response to LHRH in cycling gilts. Oestrous cycle of 24 Landrace gilts was synchronised with Regumate (for 15 days) followed by 800 IU PMSG 24h later. In experiment 1, Antarelix (n=6 gilts) was injected i.v. (0.5mg per injection) twice daily on four consecutive days from day 3 to 6 (day 0=last day of Regumate feeding). Control gilts (n=6) received saline. Blood was sampled daily, and every 20 min for 6h on days 2, 4, 6, 8 and 10. In experiment 2, gilts (n=12) were assigned to the following treatments: Antarelix; Antarelix + 50 microg LHRH on day 4; Antarelix + 150 microg LHRH on day 4 or control, 50 microg LHRH only on day 4. Blood samples were collected daily and every 20 min for 6h on days 2, 4 and 6 to assess LH pulsatility. Ovarian follicular development was evaluated at slaughter.Antarelix suppressed (P<0.05) serum LH concentrations. The amount of LH released on days 4-9 (experiment 1) was 8.80 versus 36.54 ngml(-1) (S.E.M.=6.54). The pattern of FSH, and the preovulatory oestradiol rise was not affected by GnRH antagonist. Suppression of LH resulted in a failure (P<0.05) of postovulatory progesterone secretion. Exogenous LHRH (experiment 2) induced a preovulatory-like LH peak, however in Antarelix treated gilts the LH surge started earlier and its duration was less compared to controls (P<0.01). Furthermore, the amount of LH released from day 4 to 5 was lower (P<0.01) in Antarelix, Antarelix + 50 and Antarelix + 150 treated animals compared to controls. No differences were estimated in the number of LH pulses between days and treatment. Pulsatile FSH was not affected by treatment. Mean basal LH levels were lower (P<0.05) after antagonist treatment compared to controls. Antarelix blocked the preovulatory LH surge and ovulation, but the effects of Antarelix were reduced by exogenous LHRH treatment. The development of follicles larger than 4mm was suppressed (P<0.05) by antagonist treatment.In conclusion, Antarelix treatment during the follicular phase blocked preovulatory LH surge, while FSH and oestradiol secretion were not affected. Antarelix failed to alter pulsatile LH and FSH secretor or pituitary responsiveness to LHRH during the preovulatory period.     

Concentrations of LH,prolactin and progesterone in early-pregnant and oestradiol-treated pigs

Fifteen gilts (n = 5 per group) were used to study plasma LH, prolactin and progesterone concentrations on days 13–19 after oestrus in early-pregnant, oestradiol-treated (5 mg, administered on days 11–15) and control cycling pigs.Peripheral blood samples were taken without stress at one-hour intervals for 12 h on days 13–14, 15–16 and 18–19. There was no difference amongst groups in LH levels on days 13–14 and 15–16. The LH levels in the cycling untreated pigs was lower (P < 0.05) than in pregnant gilts on days 18–19. Concentrations of prolactin in oestradioltreated pigs were 7–20 times higher than in pregnant pigs. The greatest differences in progesterone concentrations were recorded on days 18–19. Progesterone levels were less (P < 0.01) in oestrogen-treated gilts (14.54±1.09 ng/ml) when compared with pregnant gilts (24.23 ± 4.10). A comparison of the secretion patterns for the three hormones showed that injections of oestradiol given to the cycling gilt did not result in patterns which fully imitate the implantation period of natural pregnancy in the pig.